144 related articles for article (PubMed ID: 33353858)
21. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
22. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
23. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
[TBL] [Abstract][Full Text] [Related]
24. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
25. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study.
Hatanaka T; Kakizaki S; Uehara D; Nagashima T; Ueno T; Namikawa M; Saito S; Hosonuma K; Suzuki H; Naganuma A; Takagi H; Sato K; Uraoka T
Intern Med; 2019 Jul; 58(13):1835-1844. PubMed ID: 30918170
[TBL] [Abstract][Full Text] [Related]
26. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study.
Vitale A; Farinati F; Pawlik TM; Frigo AC; Giannini EG; Napoli L; Ciccarese F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Sacco R; Cabibbo G; Virdone R; Marra F; Felder M; Morisco F; Benvegnù L; Gasbarrini A; Svegliati-Baroni G; Foschi FG; Missale G; Masotto A; Nardone G; Colecchia A; Bernardi M; Trevisani F; Cillo U
Liver Int; 2019 Aug; 39(8):1478-1489. PubMed ID: 31131974
[TBL] [Abstract][Full Text] [Related]
27. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Korea.
Lee MJ; Chang SW; Kim JH; Lee YS; Cho SB; Seo YS; Yim HJ; Hwang SY; Lee HW; Chang Y; Jang JY
Invest New Drugs; 2021 Feb; 39(1):260-268. PubMed ID: 32749658
[TBL] [Abstract][Full Text] [Related]
28. Presentation and Outcomes of Hepatocellular Carcinoma in the Arabian Peninsula: A Review of a Single Institution Experience in the Sorafenib Era.
Shaaban A; Salamah R; Abo Elseud Y; Mohanty A; Albarrak J
J Gastrointest Cancer; 2021 Mar; 52(1):85-89. PubMed ID: 31808059
[TBL] [Abstract][Full Text] [Related]
29. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
30. The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib.
Yılmaz A; Şimşek M; Hannarici Z; Büyükbayram ME; Bilici M; Tekin SB
Future Oncol; 2021 Nov; 17(33):4545-4559. PubMed ID: 34431372
[No Abstract] [Full Text] [Related]
31. Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma.
Fang JH; Xu L; Shang LR; Pan CZ; Ding J; Tang YQ; Liu H; Liu CX; Zheng JL; Zhang YJ; Zhou ZG; Xu J; Zheng L; Chen MS; Zhuang SM
Hepatology; 2019 Sep; 70(3):824-839. PubMed ID: 30506570
[TBL] [Abstract][Full Text] [Related]
32. Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.
op den Winkel M; Nagel D; Sappl J; op den Winkel P; Lamerz R; Zech CJ; Straub G; Nickel T; Rentsch M; Stieber P; Göke B; Kolligs FT
PLoS One; 2012; 7(10):e45066. PubMed ID: 23071507
[TBL] [Abstract][Full Text] [Related]
33. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
34. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
35. Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Satani M; Niizeki T; Okamura S; Iwamoto H; Shimose S; Shirono T; Noda Y; Koga H; Torimura T;
Oncotarget; 2016 Sep; 7(39):64400-64409. PubMed ID: 27462865
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Imedio ER; Beveridge RD; Urtasun JA; Campos GB; Estellés DL; Esparcia MF; Daroqui JC; Huerta ÁS; Ortiz AG; Salcedo JM
Med Oncol; 2014 May; 31(5):948. PubMed ID: 24740650
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Choi GH; Han S; Shim JH; Ryu MH; Ryoo BY; Kang YK; Kim KM; Lim YS; Lee HC
Am J Clin Oncol; 2017 Apr; 40(2):167-174. PubMed ID: 25268070
[TBL] [Abstract][Full Text] [Related]
38. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
[TBL] [Abstract][Full Text] [Related]
39. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
40. Development and External Validation of the Munich Sorafenib Evaluation Score for Hepatocellular Carcinoma.
Op den Winkel M; Nagel D; Seidensticker M; De Toni EN; Merz J; Op den Winkel J; Öcal O; Stecher SS; Bourhis H; Malfertheiner P; Mayerle J; Ricke J; Kolligs FT
Dig Dis; 2023; 41(2):268-281. PubMed ID: 35421865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
